Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 16/20 | 0.57 |
| ▸ | PDE4B | Q07343 | 13/20 | 0.57 |
| ▸ | PDE4C | Q08493 | 13/20 | 0.57 |
| ▸ | PDE4D | Q08499 | 13/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.50 |
| ▸ | FPR2 | P25090 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL498077 | 0.85 | PDE4D (0.48) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL497977 | 0.84 | PDE4A (0.55) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL5823060 | 0.81 | PDE4A (0.77) | PDE4APDE4BPDE4CPDE4DFPR2 | |
| SCHEMBL8632255 | 0.78 | PDE4A (0.71) | PDE4APDE4BPDE4CPDE4DHRH3 | |
| SCHEMBL127547 | 0.78 | PDE4A (0.50) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL2372201 | 0.77 | PDE4A (0.61) | PDE4APDE4BPDE4CPDE4DFPR2 | |
| SCHEMBL8631909 | 0.77 | PDE4A (0.70) | PDE4APDE4BPDE4CPDE4DHRH3 | |
| SCHEMBL497699 | 0.77 | PDE4A (0.56) | PDE4APDE4BPDE4CPDE4DFPR2 | |
| SCHEMBL5823404 | 0.77 | PDE4A (0.62) | PDE4APDE4BPDE4CPDE4DFPR2 | |
| SCHEMBL3375192 | 0.76 | MAPT (0.69) | PDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2157084-B1 | 5-PHENYL-3-PYRIDAZINONE DERIVATIVE | KOWA CO (JP) | 2013-05-22 | — | — | EP | disclosed |
| US-8106053-B2 | 5-phenyl-3-pyridazinone derivative | KOWA COMPANY, LTD. | 2012-01-31 | — | — | US | disclosed |
| US-20100197698-A1 | 5-PHENYL-3-PYRIDAZINONE DERIVATIVE | KOWA COMPANY, LTD. (JP) | 2010-08-05 | — | — | US | disclosed |
| EP-2157084-A1 | 5-PHENYL-3-PYRIDAZINONE DERIVATIVE | Kowa Company, Ltd. (JP) | 2010-02-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197698-A1 | 5-PHENYL-3-PYRIDAZINONE DERIVATIVE | SERPINE1, MMP1, PLAT | PDE4A 2167/4885PDE4B 1932/4885PDE4C 2802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.